Abstract
We report the results of a case-control study designed to analyze the relationship between oral contraceptive use (OC) and the risk of cutaneous malignant melonama (MM) in 240 White women under the age of 45. Five French centers participated in the study between February 1982 and January 1987 for periods of eight to 54 months, depending on the center. Cases were 91 consecutive newly diagnosed patients with histologically verified MM. Each case was matched with one or two controls on year of birth, date of interview, and treatment center. Controls were 149 patients with either malignant or nonmalignant disease who came to the center for diagnosis and treatment. Odds ratios (OR) were estimated by multivariate analyses taking into account age at menarche, sunlight exposure, and skin characteristics. No significant relation was found between the risk of MM and the total duration of OC use, age at start of use, and elapsed time since the first OC use. However, when the analysis was restricted to women aged 30–40 years, i.e., those who were able to use OC for 10 years or more, or who had started OC use 15 years or more before the diagnosis, the risk of MM increased significantly with the duration of OC use (P=0.03). A total of more than 4,000 hours of sunlight exposure, and menarche before the age of 14 also were found to increase significantly the risk of MM (OR=5.4, 95 percent confidence interval [CI]=1.6−18.3; and OR=3.6, CI=1.0−12.5, respectively).
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Snell RS, Bischitz PG. The effect of large doses of estrogen and estrogen and progesterone on melanin pigmentation. J Invest Dermatol 1960; 35: 73–82.
Fisher RI, Neifeld JP, Lippman ME. Estrogen receptors in human malignant melanoma. Lancet 1976; 2: 337–8.
Creagan ET, Ingle JN, Woods JE, Pritchard DJ, Jiang NS. Estrogen receptors in patients with malignant melanoma. Cancer 1980; 46: 1785–6.
Avril MF, Delarue JC, Prade M. Récepteurs oestrogéniques et progestéroniques dans les mélanomes malins, les naevi pigmentaires bénins et les épithéliomas basocellulaires. Pathol Biol 1985; 33: 39–44.
Flowers J, Seigler H, MacCarty K Sr, Konrath J, MacCarty KJr. Absence of estrogen receptor in human melanoma as evaluated by a monoclonal antiestrogen receptor antibody. Arch Dermatol 1987; 123: 764–5.
Karakousis CP, Lopez RE, Bhakoo HS, Rosen F, Hoore R, Carlson M. Estrogen and progesterone receptors and Tamoxifen in malignant melanoma. Cancer Treat Rep 1980; 64: 819–27.
Beral V, Ramcharan S, Faris R. Malignant melanoma and oral contraceptive use among women in California. Br J Cancer 1977; 36: 804–9.
Adam SA, Sheaves JK, Wright NH, Mosser RW, Vessey MP. A case-control study of the possible association between oral contraceptives and malignant melanoma. Br J Cancer 1981; 44: 45–50.
Kay CR. Malignant melanoma and oral contraceptive (Letter). Br J Cancer 1981; 44: 479.
Bain C, Hennekens CH, Speizer FE, Rosner B, Willett W, Belanger C. Oral contraceptive use and malignant melanoma. JNCI 1982; 68: 537–9.
Holly EA, Weiss NS, Liff JM. Cutaneous melanoma in relation to exogenous hormones and reproductives factors. JNCI 1983, 70: 827–31.
Beral V, Evans S, Shaw H, Milton G. Oral contraceptive use and malignant melanoma in Australia. Br J Cancer 1984; 50: 681–5.
Helmrich SP, Rosenberg L, Kaufman DW, et al. Lack of an elevated risk of malignant melanoma in relation to oral contraceptive use. JNCI 1984; 72: 617–20.
Holman CDJ, Armstrong BK, Heenan PJ. Cutaneous malignant melanoma in women: exogenous sex hormones and reproductive factors. Br J Cancer 1984; 50: 673–80.
Gallagher RP, Ellwood JM, Hill CB, Coldman AJ, Threlfall WJ, Spinelli JJ. Reproductive factors, oral contraceptives and risk of malignant melanoma: Western Canada melanoma study. Br J Cancer 1985; 52: 901–7.
Osterlind A, Tucker MA, Stone BJ, Jensen OM. The Danish case-control study of cutaneous malignant melanoma. III. Hormonal and reproductive factors in women. Int J Cancer 1988; 42: 821–4.
Breslow NE, Day NE, Halvorsen DT, Prentice RL, Sabai C. Estimation of multiple relative risk function in matched case control study. Am J Epidemiol 1978; 108: 299–306.
Breslow NE, Day NE. Statistical methods in cancer research. Breslow NE and Day NE Eds. Lyon, France: International Agency for Research on Cancers, 1980. IARC Sci. Pub. No. 32.
Mickey RM, Greenland S. The impact of confounder selection criteria on effect estimation. Am J Epidemiol 1989; 129: 125–37.
Hoover R, Bain C, Cole P, MacMahon B. Oral contraceptive use: association with frequency of hospitalization and chronic disease risk indicators. Am J Public Health 1978; 68: 335–41.
Holly EA. Current issues in melanoma research: exogenous hormones, pregnancy. Recent Results in Cancer Res 1986; 102: 108–17.
Author information
Authors and Affiliations
Additional information
This study was made possible by a grant from the Institut Goustave Roussy (Contract no. 85-D-9).
Rights and permissions
About this article
Cite this article
Lê, M.G., Cabanes, P.A., Desvignes, V. et al. Oral contraceptive use and risk of cutaneous malignant melanoma in a case-control study of French women. Cancer Causes Control 3, 199–205 (1992). https://doi.org/10.1007/BF00124252
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00124252